About Immunocore Holdings plc
https://www.immunocore.comImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
CEO
Bahija Jallal
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Oppenheimer
Outperform
JP Morgan
Overweight
Morgan Stanley
Equal Weight
Mizuho
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:7.06M
Value:$234.03M
RTW INVESTMENTS, LP
Shares:4.87M
Value:$161.34M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.78M
Value:$158.39M
Summary
Showing Top 3 of 140
About Immunocore Holdings plc
https://www.immunocore.comImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $103.69M ▲ | $110.35M ▼ | $785K ▲ | 0.76% ▲ | $0.02 ▲ | $4.14M ▲ |
| Q2-2025 | $97.96M ▲ | $111.8M ▲ | $-10.3M ▼ | -10.51% ▼ | $-0.21 ▼ | $-6.4M ▼ |
| Q1-2025 | $93.88M ▲ | $96.67M ▼ | $5.02M ▲ | 5.35% ▲ | $0.1 ▲ | $9.96M ▲ |
| Q4-2024 | $84.05M ▲ | $103.17M ▲ | $-23.77M ▼ | -28.28% ▼ | $-0.47 ▼ | $-15.27M ▼ |
| Q3-2024 | $80.25M | $88.3M | $8.74M | 10.89% | $0.17 | $10.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $892.35M ▲ | $1.1B ▲ | $705.94M ▲ | $396.56M ▲ |
| Q2-2025 | $882.81M ▲ | $1.08B ▲ | $693.91M ▲ | $388.48M ▲ |
| Q1-2025 | $837.03M ▲ | $1.03B ▲ | $649.53M ▲ | $378.48M ▲ |
| Q4-2024 | $820.38M ▼ | $1.01B ▼ | $648.79M ▼ | $360.72M ▼ |
| Q3-2024 | $901.28M | $1.08B | $706.81M | $377.83M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-177K ▲ | $-4.46M ▼ | $5.25M ▲ | $1.87M ▼ | $10.48M ▼ | $-5.2M ▼ |
| Q2-2025 | $-10.3M ▼ | $25.96M ▲ | $-30.41M ▼ | $3.67M ▲ | $11.09M ▼ | $25.55M ▲ |
| Q1-2025 | $5.02M ▲ | $435K ▲ | $9.7M ▲ | $2.55M ▲ | $21.11M ▲ | $137K ▲ |
| Q4-2024 | $-23.55M ▼ | $-13.95M ▼ | $-3.54M ▼ | $-51.51M ▼ | $-82.04M ▼ | $-17.54M ▼ |
| Q3-2024 | $8.74M | $21.13M | $-828K | $198K | $32.78M | $20.3M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Sale of Therapies | $80.00M ▲ | $90.00M ▲ | $100.00M ▲ | $100.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 International | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Rest of World | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $60.00M ▲ | $70.00M ▲ | $60.00M ▼ | $60.00M ▲ |
CEO
Bahija Jallal
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Oppenheimer
Outperform
JP Morgan
Overweight
Morgan Stanley
Equal Weight
Mizuho
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:7.06M
Value:$234.03M
RTW INVESTMENTS, LP
Shares:4.87M
Value:$161.34M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.78M
Value:$158.39M
Summary
Showing Top 3 of 140